Annovis Bio, Inc. (ANVS): Results of Operations and Financial Condition
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Annovis Bio, Inc. (the “Company”) is providing the following information about its preliminary cash and cash equivalents as of September 30, 2026. Based on preliminary estimates and currently available information, the Comp
How this was made
The 30-second read
Why it matters
The disclosure provides the first public insight into the company's near‑term cash runway, which is modest and may affect valuation.
Market read
The low cash estimate could trigger a sell‑off in ANVS and influence sentiment toward cash‑strained biotech stocks.
What to watch
Potential undisclosed credit facilities or convertible securities could improve liquidity.
Annovis Bio preliminarily estimates cash and cash equivalents of approximately $2.8 million as of September 30, 2026; quarterly financial statements and closing processes are not complete.
The filing reports only a preliminary, unaudited cash estimate of approximately $2.8 million and provides no operating, income statement, cash flow, or guidance metrics for the three and nine months ended September 30, 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash and cash equivalents as of September 30, 2026other | approximately $2.8 million | – | – |
Concerns
- The filing provides no revenue, expense, profitability, EPS, operating cash flow, or free cash flow results.
- Actual results for the three and nine months ended September 30, 2026 may differ from the preliminary estimates after closing procedures, final adjustments and management review.
- The Company states that the preliminary estimates are not indicative of results expected for any future period.
- The reported cash and cash equivalents figure is preliminary and unaudited.
What to watch
- Completion of the quarterly financial closing processes for the period ended September 30, 2026.
- Release of interim financial statements for the three and nine months ended September 30, 2026.
- Any change to the preliminary estimate of cash and cash equivalents of approximately $2.8 million.
Balance sheet and cash flow
- The Company estimates that its cash and cash equivalents were approximately $2.8 million as of September 30, 2026.
- The cash and cash equivalents estimate is preliminary, unaudited and subject to change.
- The Company has not yet completed its quarterly financial closing processes for the period ended September 30, 2026.
- The Company’s independent registered public accounting firm has not conducted a review of and does not express an opinion or any other form of assurance with respect to these preliminary estimates.
Analysis
This Form 8-K is not a full earnings release. Annovis Bio disclosed only a preliminary estimate that cash and cash equivalents were approximately $2.8 million as of September 30, 2026. The Company explicitly states that its interim financial statements for the three and nine months ended September 30, 2026 are not yet available.
The disclosure contains no reported revenue, operating expenses, operating loss or income, net loss or income, EPS, segment results, gross margin, operating cash flow, free cash flow, debt, or capital-return information. As a result, the filing does not provide evidence on demand, operating performance, expense trends, profitability, margins, or business mix for the reported period.
The central item for investors is the preliminary liquidity figure. Management characterizes the approximately $2.8 million cash and cash equivalents amount as based on preliminary estimates and currently available information. It says the figure is unaudited, subject to change, and may differ after financial closing procedures, final adjustments, and management review.
The filing also notes that the independent registered public accounting firm has not reviewed the preliminary estimate and does not provide assurance on it. The next relevant disclosure will be the completed interim financial statements for the three and nine months ended September 30, 2026, including any finalized cash balance and the operating and cash-flow results absent from this filing.
Not in the filing
stated, not guessed- Revenue for the three months ended September 30, 2026
- Revenue for the nine months ended September 30, 2026
- Prior-year revenue comparisons
- Prior-quarter revenue comparison
- Segment revenue and segment growth
- Gross profit and gross margin
- Operating expenses
- Operating income or loss
- Net income or loss
- GAAP EPS
- Non-GAAP EPS
- Operating cash flow
- Free cash flow
- Debt
- Cash and cash equivalents comparison with prior year or prior quarter
- Share repurchases
- Dividends
- Forward revenue guidance
- Forward gross-margin guidance
- Forward operating-expense guidance
- Forward tax-rate guidance
- Prior guidance for comparison
- Management earnings commentary or named executive quotes
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Annovis Bio filed a Form 8‑K reporting preliminary cash figures for the quarter ended Sep 30 2026.
Ticker impact
Form 8‑K discloses preliminary cash of about $2.8 million as of Sep 30 2026, the first public estimate of the company's liquidity.
likely downside as market prices in cash constraints
Preliminary cash estimate is materially low for a biotech; investors may reassess runway and risk.
Market effects
May raise concerns for other cash‑constrained biotech firms.
Limited to U.S. small‑cap biotech segment.
Minimal
Counterpoint
If the company secures a partnership or financing soon, the cash shortfall could be temporary.
Key entities
- companyAnnovis Bio, Inc.
Biopharmaceutical company reporting preliminary cash balance.
